Impax Laboratories, Inc., a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved its generic version of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg. The company is preparing for commercialisation of this product through Impax's generic division.
"We are pleased to receive approval of generic glyburide tablets, a product that was developed at our Middlesex, NJ facility," said Fred Wilkinson, president and chief executive officer of Impax.
According to IMS Health (NSP), US brand and generic sales of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg products were approximately $14 million for the 12 months ending in August 2015.
Subscribe to PharmaTutor News Alerts by Email >>
